Literature DB >> 8123759

Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.

S Kooi1, R S Freedman, J Rodriguez-Villanueva, C D Platsoucas.   

Abstract

The ability of T-cell lines derived from tumor-infiltrating lymphocytes (TIL) from patients with ovarian carcinoma to produce interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and IL-6 in response to autologous or allogeneic ovarian carcinoma tumor cells was determined. These T-cell lines were derived in low concentrations of recombinant IL-2 (rIL-2), 200 IU/ml. Certain of these T-cell lines (3 of 7) exhibited antigen-independent (spontaneous) production of moderate to low concentrations of IFN-gamma (75 to 112 pg/ml), TNF-alpha (62-88 pg/ml), and IL-6 (38 to 690 pg/ml), in culture medium alone in the absence of rIL-2, tumor cells or polyclonal activators. Addition of 20 IU/ml of rIL-2 to the cultures resulted in a significant increase of the antigen-independent production of IFN-gamma (range 75-6480 pg/ml) by all seven T-cell lines and TNF-alpha (44-490 pg/ml) by 5 of 7 T-cell lines. Certain T-cell lines (4 of 7) exhibited antigen-independent production of IL-6 (38-690 pg/ml), which was not affected by the addition of 20 IU/ml of rIL-2. Certain TIL-derived T-cell lines (2 of 7) produced IFN-gamma, TNF-alpha, and IL-6 in response to stimulation with autologous ovarian tumor cells, in the presence of 20 IU/ml of rIL-2. Irradiated autologous ovarian tumor cells alone or in the presence of rIL-2 did not produce any detectable levels of IFN-gamma, TNF-alpha, or IL-6 during the 6 day culture.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8123759

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  13 in total

Review 1.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 3.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

4.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

Authors:  Wei-Ting Hwang; Sarah F Adams; Emin Tahirovic; Ian S Hagemann; George Coukos
Journal:  Gynecol Oncol       Date:  2011-10-29       Impact factor: 5.482

5.  Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.

Authors:  Anna Maria Chiaravalli; Maddalena Feltri; Valentina Bertolini; Elena Bagnoli; Daniela Furlan; Roberta Cerutti; Raffaele Novario; Carlo Capella
Journal:  Virchows Arch       Date:  2005-10-27       Impact factor: 4.064

6.  Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.

Authors:  B Melichar; M A Nash; R Lenzi; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 7.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

8.  Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients.

Authors:  Susan K Lutgendorf; Donald M Lamkin; Koen DeGeest; Barrie Anderson; Minh Dao; Stephanie McGinn; Bridget Zimmerman; Heena Maiseri; Anil K Sood; David M Lubaroff
Journal:  Brain Behav Immun       Date:  2008-02-13       Impact factor: 7.217

9.  Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.

Authors:  M A Nash; R Lenzi; C L Edwards; J J Kavanagh; A P Kudelka; C F Verschraegen; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

10.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.